Skip to main content

Advertisement

SpringerLink
Log in

EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis

  • Clinical Trial
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The epidermal growth factor receptor (EGFR) is one of the four human epidermal receptors. The efficacy and safety of EGFR-targeted therapies for treating non-small-cell lung cancer (NSCLC) remained controversial. The aim of this study was to systematically evaluate EGFR-targeted therapies plus chemotherapy for advanced NSCLC.

Methods

Cochrane Central Register of Controlled Trials, PubMed, and Embase were searched for relevant studies. Quantitative analysis was carried out to evaluate survival, response, and toxicity of EGFR-targeted therapies.

Results

Ten randomized controlled trials (RCTs) involving 5,936 patients were identified out of 107 studies. There was no statistical difference in overall (OS) and 1-year (OYS) survival rate when small-molecule tyrosine kinase inhibitors (TKIs) plus platinum-based doublet chemotherapy (PBDC) were compared with PBDC alone. However, progression-free survival [hazard ratio (HR) = 0.87, 95% confidence interval (CI) 0.76–0.99] and overall response rate (ORR) were marginally improved. Prolonged OS (HR = 0.87, 95% CI 0.78–0.96) and increased ORR and OYS were found when cetuximab plus PBDC was compared with PBDC alone. Adverse events in the combination arms were similar in incidence to those of the chemotherapy-alone arms, with the exception of an increased incidence of rash and diarrhea.

Conclusions

Cetuximab adds benefits to NSCLC patients compared with PBDC alone. Small-molecule TKIs plus PBDC lead to a slightly additive efficacy compared with PBDC alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  2. Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594

    Article  PubMed  Google Scholar 

  3. Stinchcombe TE, Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6:233–241

    Article  CAS  PubMed  Google Scholar 

  4. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  5. Grunwald V, Hidalgo M (2002) The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 26:109–164

    Article  PubMed  Google Scholar 

  6. Brandes AA, Franceschi E, Tosoni A et al (2008) Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 14:957–960

    Article  CAS  PubMed  Google Scholar 

  7. Saif MW, Merikas I, Tsimboukis S et al (2008) Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. Jop 9:267–274

    PubMed  Google Scholar 

  8. Mok TS, Wu YL, Yu CJ et al (2009) Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 27:5080–5087

    Article  CAS  PubMed  Google Scholar 

  9. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899

    Article  CAS  PubMed  Google Scholar 

  10. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    Article  CAS  PubMed  Google Scholar 

  11. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834

    Article  CAS  PubMed  Google Scholar 

  12. Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545–1552

    Article  CAS  PubMed  Google Scholar 

  13. Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 22:777–784

    Article  CAS  PubMed  Google Scholar 

  14. Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 22:785–794

    Article  CAS  PubMed  Google Scholar 

  15. Heymach JV, Paz-Ares L, De Braud F et al (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407–5415

    Article  CAS  PubMed  Google Scholar 

  16. Lynch TJ, Patel T, Dreisbach L et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911–917

    Article  CAS  PubMed  Google Scholar 

  17. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531

    Article  CAS  PubMed  Google Scholar 

  18. Rosell R, Robinet G, Szczesna A et al (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19:362–369

    Article  CAS  PubMed  Google Scholar 

  19. Butts CA, Bodkin D, Middleman EL et al (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25:5777–5784

    Article  CAS  PubMed  Google Scholar 

  20. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  PubMed  Google Scholar 

  21. Hotta K, Ueoka H, Kiura K, Tabata M, Ogino A, Umemura S (2005) Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol 44:717–722

    Article  CAS  PubMed  Google Scholar 

  22. Koyama N, Yasuto J, Takabe K, Yoshizawa M, Usui Y, Inase N (2006) The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer. Anticancer Res 26:4519–4526

    CAS  PubMed  Google Scholar 

  23. D’Addario G, Pintilie M, Leighl NB, Feldd R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936

    Article  PubMed  Google Scholar 

  24. Kunkel MW, Hook KE, Howard CT et al (1996) Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs 13:295–302

    Article  CAS  PubMed  Google Scholar 

  25. Akita RW, Sliwkowski MX (2003) Preclinical studies with Erlotinib (Tarceva). Semin Oncol 30:15–24

    Article  CAS  PubMed  Google Scholar 

  26. Baselga J (2004) Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 22:759–761

    Article  CAS  PubMed  Google Scholar 

  27. Liu L, Cao Y, Tan A et al (2010) Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 65:849–861

    Article  CAS  PubMed  Google Scholar 

  28. Chia-Hsuin Chang K-YC, Yinong Young-Xu, Tobias Kurth, John Orav E, Pan-Chyr Yang, Arnold Chan K (2008) The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: A meta-analysi. Lung Cancer 62:242–252

    Article  PubMed  Google Scholar 

  29. Rajeswaran A, Trojan A, Burnand B et al (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemothera\peutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59:1–11

    Article  PubMed  Google Scholar 

  30. McDonald MA, Simpson SH, Ezekowitz JA et al (2005) Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 331:873

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

All authors declare no potential conflict of interest.

Author information

Authors and Affiliations

  1. Department of Stomatology, Chinese People’s Liberation Army General Hospital, No.28 Fuxing Road, Haidian District, Beijing, 100853, People’s Republic of China

    Peng Chen, Hai-Zhong Zhang & Hong-Chen Liu

  2. Company 11, Second Military Medical University, 800 Xiangyin Road, Shanghai, 200433, People’s Republic of China

    Long Wang

  3. Department of Stomatology, the General Hospital of the Air Force of the Chinese People’s Liberation Army, No.30 Fucheng Road, Haidian District, Beijing, 100142, People’s Republic of China

    Bing Liu

  4. Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai, 200003, People’s Republic of China

    Long Wang & Zui Zou

Authors
  1. Peng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Long Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hai-Zhong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong-Chen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zui Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zui Zou.

Additional information

Peng Chen, Long Wang, and Bing Liu contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, P., Wang, L., Liu, B. et al. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 67, 235–243 (2011). https://doi.org/10.1007/s00228-010-0965-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-010-0965-4

Keyword

Search

Navigation